EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)

• Status: Completed
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy of EDG004 compared to placebo for the treatment of adult patients with GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. (DSM-5) and confirmed by the Mini International Neuropsychiatric Interview (MINI 7.0). Efficacy will be measured by a statistically significant greater mean reduction from baseline compared to endpoint in anxiety symptoms as measured by the total score of the clinician-rated Hamilton Rating Scale for Anxiety (HAM-A) for the EDG004 treatment group compared to placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Edgemont Pharmaceuticals, LLC
• Treatments: Lorazepam

Criteria

Inclusion Criteria:

• Men and women between the ages of 18-65 years and

• Diagnosed with GAD and

• No other psychiatric conditions, and are otherwise medically healthy.

Exclusion Criteria:

• Women who are pregnant or lactating.